Harry P. Erba
哈里·厄巴
MD, PhD
Professor of Medicine, Director of Hematologic Malignancies Program医学教授，血液恶性肿瘤项目主任
👥Biography 个人简介
Dr. Harry Erba is a prominent hematologic oncologist specializing in AML, MDS, and myeloproliferative neoplasms. He has led major clinical trials on targeted therapies including IDH inhibitors, antibody-drug conjugates, and hypomethylating agent combinations, advancing treatment for older and unfit patients with these diseases.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Targeted Therapy in AML and MDS
Led key trials establishing enasidenib, ivosidenib, and venetoclax-based regimens for older or unfit AML patients, fundamentally expanding the therapeutic armamentarium beyond intensive chemotherapy.
Myeloproliferative Neoplasm Management
Contributed seminal research on JAK inhibitors and novel agents in myelofibrosis and polycythemia vera, improving symptom control and outcomes in MPNs.
Representative Works 代表性著作
Enasidenib in Mutant IDH2 Relapsed or Refractory AML
Blood (2017)
Pivotal phase I/II trial showing enasidenib induces durable responses in IDH2-mutated relapsed/refractory AML, leading to FDA approval.
Venetoclax Combined with Decitabine or Azacitidine in AML
Journal of Clinical Oncology (2020)
Demonstrated high response rates and improved survival with venetoclax plus HMA in older/unfit AML patients ineligible for intensive chemotherapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elihu Estey
Fred Hutchinson Cancer Center
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Naval Daver
The University of Texas MD Anderson Cancer Center
Courtney DiNardo
The University of Texas MD Anderson Cancer Center
关注 哈里·厄巴 的研究动态
Follow Harry P. Erba's research updates
留下邮箱，当我们发布与 Harry P. Erba（Duke Cancer Institute, Duke University Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment